

**COMPUGEN LTD.**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(U.S. dollars in thousands, except for share and per-share amounts)

	<b>Three Months Ended</b>		<b>Year Ended</b>	
	<b>December 31,</b>		<b>December 31,</b>	
	<b>2015</b>	<b>2014</b>	<b>2015</b>	<b>2014</b>
<b>Revenues</b>	8,313	6,552	9,277	12,367
Cost of revenues	1,036	987	1,633	3,344
<b>Gross profit</b>	<u>7,277</u>	<u>5,565</u>	<u>7,644</u>	<u>9,023</u>
<b>Operating expenses</b>				
Research and development expenses, net	5,801	4,848	21,245	15,074
Marketing and business development expenses	564	400	1,309	838
General and administrative expenses	1,639	1,432	6,008	5,448
<b>Total operating expenses</b>	<u>8,004</u>	<u>6,680</u>	<u>28,562</u>	<u>21,360</u>
<b>Operating loss</b>	<b>(727)</b>	<b>(1,115)</b>	<b>(20,918)</b>	<b>(12,337)</b>
Financing and other income (loss), net	645	(67)	1,145	1,603
<b>Net loss before taxes</b>	<b>(82)</b>	<b>(1,182)</b>	<b>(19,773)</b>	<b>(10,734)</b>
Taxes on income	390	300	390	360
<b>Net loss</b>	<u><b>(472)</b></u>	<u><b>(1,482)</b></u>	<u><b>(20,163)</b></u>	<u><b>(11,094)</b></u>
Basic net loss per ordinary share	(0.01)	(0.03)	(0.40)	(0.23)
Weighted average number of ordinary shares used in computing basic net loss per share	50,526,584	50,144,787	50,437,040	47,808,855
Diluted net loss per ordinary share	(0.01)	(0.03)	(0.40)	(0.26)
Weighted average number of ordinary shares used in computing diluted net loss per share	50,526,584	50,144,787	50,437,040	48,387,063

**COMPUGEN LTD.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
**DATA**  
(U.S. dollars, in thousands)

	<b>December 31,</b>	
	<b>2015</b>	<b>2014</b>
<b>ASSETS</b>		
<b>Current assets</b>		
Cash, cash equivalents, short-term bank deposits and restricted cash	81,421	73,328
Investment in Evogene	426	1,054
Trade receivable	7,800	-
Other accounts receivable and prepaid expenses	1,352	716
<b>Total current assets</b>	<b>90,999</b>	<b>75,098</b>
<b>Non-current assets</b>		
Long-term bank deposits	-	35,026
Non-current prepaid expenses	101	108
Severance pay fund	2,179	2,024
Property and equipment, net	6,028	2,730
<b>Total non-current assets</b>	<b>8,308</b>	<b>39,888</b>
<b>Total assets</b>	<b>99,307</b>	<b>114,986</b>
<b>LIABILITIES AND SHAREHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Other account payables, accrued expenses and trade payables	6,542	4,379
Deferred revenues	312	1,789
Research and development funding arrangement	-	421
<b>Total current liabilities</b>	<b>6,854</b>	<b>6,589</b>
<b>Non-current liabilities</b>		
Accrued severance pay	2,556	2,281
<b>Total non-current liabilities</b>	<b>2,556</b>	<b>2,281</b>
<b>Total shareholders' equity</b>	<b>89,897</b>	<b>106,116</b>
<b>Total liabilities and shareholders' equity</b>	<b>99,307</b>	<b>114,986</b>